DKK1 emerges as pleiotropic regulator and promising therapeutic target in head and neck squamous cell carcinoma
Background
Head and neck squamous cell carcinoma (HNSCC) is a prevalent malignancy with persistently high incidence, recurrence, and mortality rates globally. This poses a significant public health challenge, partly due to the complex molecular networks driving its progression. Dickkopf-1 (DKK1), a classical secreted antagonist of the Wnt signaling pathway, has garnered considerable attention. Its diverse roles in tumor initiation, progression, and therapeutic resistance suggest it could address critical gaps in current HNSCC management and prognostic assessment.
Study Design
This narrative review systematically synthesized current research on Dickkopf-1 (DKK1) in head and neck squamous cell carcinoma (HNSCC). Researchers discussed regulatory mechanisms of DKK1 expression, its prognostic significance, pro-tumorigenic molecular mechanisms, and immunomodulatory functions. The review also explored DKK1's clinical translational potential as a biomarker and therapeutic target, aiming to provide novel insights into HNSCC pathogenesis and establish a theoretical foundation for advancing DKK1-based precision diagnostics and therapeutic strategies.
Results
Dickkopf-1 (DKK1) plays pleiotropic roles in HNSCC, influencing tumor initiation, progression, and therapeutic resistance through both
canonicalandnon-canonical Wnt pathways. Its expression is highly spatiotemporal and context-dependent, regulated by a complex molecular network. DKK1 exhibits significant prognostic value in HNSCC, indicating its potential as a predictive biomarker. The review elucidated specific pro-tumorigenic molecular mechanisms mediated by DKK1, contributing to malignant progression. Furthermore, DKK1 demonstrates crucial immunomodulatory functions within the tumor microenvironment, impacting immune evasion and therapeutic responses. These findings collectively establish a theoretical foundation for developing DKK1-based precision diagnostics and therapeutic strategies.
Key Findings
- DKK1 plays pleiotropic roles in HNSCC tumor initiation, progression, and therapeutic resistance.
- DKK1 expression is regulated by complex canonical and non-canonical Wnt pathways.
- DKK1 exhibits high spatiotemporal specificity and context dependency in HNSCC.
- DKK1 holds prognostic significance as a biomarker in HNSCC.
- DKK1 demonstrates pro-tumorigenic molecular mechanisms and immunomodulatory functions.
Why It Matters
DKK1's multifaceted role in HNSCC progression suggests it could be a critical target for novel therapies and diagnostics. For clinicians, DKK1 offers a promising avenue for improved prognostic assessment and personalized treatment strategies, moving beyond current standard-of-care limitations. Understanding its immunomodulatory functions could lead to combination therapies that enhance existing immunotherapies by modulating the tumor microenvironment. While not a direct peptide protocol, this review lays the groundwork for future research into DKK1-targeting peptides or small molecules, potentially transforming how HNSCC is managed. The translational outlook is significant, aiming for DKK1-based precision medicine.
hnscc
dkk1
wnt-pathway
cancer
oncology
biomarker